Ponatinib and STAT5 Inhibitor Pimozide Combined Synergistic Treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid Leukemia Cells

Tezcanli Kaymaz, BurcinGumus, NurcanCelik, BesneAlcitepe, IlaydaBiray Avci, CigirAktan, Cagdas2024-08-312024-08-3120241079-99071557-7465https://doi.org/10.1089/jir.2023.0170https://hdl.handle.net/11454/105111Chronic myeloid leukemia (CML) is a clonal myeloproliferative hematological disease characterized by the chimeric breakpoint-cluster region/Abelson kinase1 (BCRen10.1089/jir.2023.0170info:eu-repo/semantics/closedAccessPonatinibCombination TherapyCytokinesStat5 Inhibitor PimozideDrug ResistancePonatinib and STAT5 Inhibitor Pimozide Combined Synergistic Treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid Leukemia CellsArticle444178189WOS:0011971901000022-s2.0-8519033364238579140Q2N/A